{"id":"W2890817079","doi":"10.1200/jco.2017.35.15_suppl.11607","title":"A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Biomarker; Breast cancer; Triple-negative breast cancer; Oncology; Cancer; Melanoma; Ovarian cancer; Internal medicine; Cancer research; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0392104,0.001135196,0.0008703928,0.0009740578,0.001065176,0.001443086,0.002594452,0.002029558,0.01755541],"category_scores_gemma":[0.01801693,0.0009963921,0.001230249,0.0009051054,0.0005705209,0.001022594,0.001492455,0.002016527,0.007465299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001217809,"about_ca_system_score_gemma":0.0064613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00170946,"about_ca_topic_score_gemma":0.003089217,"domain_scores_codex":[0.9859612,0.008634521,0.0009400809,0.001176949,0.002569255,0.0007180819],"domain_scores_gemma":[0.9859657,0.003017387,0.001818373,0.002385843,0.004142959,0.002669781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09619098,0.01475622,0.02708032,0.002910801,0.001951757,0.001810049,0.0006392848,0.002700966,0.2565585,0.003423706,0.245249,0.3467283],"study_design_scores_gemma":[0.05785134,0.1272318,0.06239067,0.0006010301,0.001920491,0.004766562,0.0002240924,0.003204536,0.1116959,0.002229934,0.6277606,0.0001230024],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.3157215,0.0187173,0.1785489,0.02100947,0.006276748,0.2185731,0.14456,0.002625634,0.09396742],"genre_scores_gemma":[0.3473551,0.005874251,0.2286157,0.01842245,0.003119794,0.1221921,0.2135552,0.001124097,0.0597413],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0392104,"threshold_uncertainty_score":0.2073669,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5247670049047602,"score_gpt":0.5941794047374243,"score_spread":0.069412399832664,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}